相似文献
1
Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1983 Oct;46(10):905-10. doi: 10.1136/jnnp.46.10.905.
2
Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit.
Neurobiol Aging. 1981 Spring;2(1):57-60. doi: 10.1016/0197-4580(81)90060-9.
3
Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls.
Psychiatry Res. 1981 Feb;4(1):21-9. doi: 10.1016/0165-1781(81)90004-4.
4
CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
Arch Neurol. 1985 May;42(5):489-92. doi: 10.1001/archneur.1985.04060050091016.
5
Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
J Neurol Neurosurg Psychiatry. 1984 May;47(5):481-4. doi: 10.1136/jnnp.47.5.481.
6
CSF monoamine metabolites in mania.
Am J Psychiatry. 1983 Apr;140(4):396-400. doi: 10.1176/ajp.140.4.396.
7
3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in human cerebrospinal fluid. Storage and measurement by reversed-phase high-performance liquid chromatography and coulometric detection using 3-methoxy-4-hydroxyphenyllactic acid as an internal standard.
J Chromatogr. 1984 Dec 12;336(2):259-69.
8
Cerebrospinal fluid monoamine metabolites during alcohol withdrawal syndrome and recovered state.
Biol Psychiatry. 1983 Oct;18(10):1141-52.
9
The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey.
Eur J Pharmacol. 1985 Mar 26;110(1):1-9. doi: 10.1016/0014-2999(85)90022-6.
10
Cerebrospinal fluid concentration of biogenic amine metabolites in idiopathic apnea of prematurity.
Biol Neonate. 1983;43(1-2):16-22. doi: 10.1159/000241633.
引用本文的文献
1
Longitudinal sex-specific impacts of high-fat diet on dopaminergic dysregulation and behavior from periadolescence to late adulthood.
Nutr Neurosci. 2025 Apr;28(4):425-438. doi: 10.1080/1028415X.2024.2377471. Epub 2024 Jul 24.
2
High-Fat Diet-Induced Weight Gain, Behavioral Deficits, and Dopamine Changes in Young C57BL/6J Mice.
Front Nutr. 2021 Jan 20;7:591161. doi: 10.3389/fnut.2020.591161. eCollection 2020.
3
Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
J Neurosci. 2020 Sep 23;40(39):7559-7576. doi: 10.1523/JNEUROSCI.1468-19.2020. Epub 2020 Aug 31.
4
Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.
Front Cell Neurosci. 2014 Nov 11;8:369. doi: 10.3389/fncel.2014.00369. eCollection 2014.
5
Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.
Brain Res. 2011 Feb 10;1373:240-52. doi: 10.1016/j.brainres.2010.12.015. Epub 2010 Dec 11.
6
Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.
Psychopharmacology (Berl). 2004 Dec;177(1-2):79-83. doi: 10.1007/s00213-004-1924-5. Epub 2004 Jun 4.
7
Platelet phenolsulphotransferase activity, monoamine oxidase activity and peripheral-type benzodiazepine binding in demented patients.
J Neural Transm (Vienna). 1996;103(4):491-501. doi: 10.1007/BF01276422.
8
Decreased beta-phenylethylamine in CSF in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1997 Dec;63(6):754-8. doi: 10.1136/jnnp.63.6.754.
9
Platelet monoamine oxidase molecular activity in demented patients.
Ital J Neurol Sci. 1997 Jun;18(3):151-6. doi: 10.1007/BF02048483.
10
Platelet monoamine oxidase B activity in parkinsonian patients.
J Neurol Neurosurg Psychiatry. 1990 Oct;53(10):854-5. doi: 10.1136/jnnp.53.10.854.
本文引用的文献
1
Brief objective measures for the determination of mental status in the aged.
Am J Psychiatry. 1960 Oct;117:326-8. doi: 10.1176/ajp.117.4.326.
2
Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit.
Neurobiol Aging. 1981 Spring;2(1):57-60. doi: 10.1016/0197-4580(81)90060-9.
3
Transitional states of central serotonin receptors in Parkinson's disease.
J Neural Transm. 1981;51(1-2):113-22. doi: 10.1007/BF01664009.
4
Monoamine oxidase activity and enzyme kinetics in three subpopulations of density-fractionated platelets in chronic paranoid schizophrenics.
Psychopharmacology (Berl). 1981;74(4):344-8. doi: 10.1007/BF00432744.
5
Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls.
Psychiatry Res. 1981 Feb;4(1):21-9. doi: 10.1016/0165-1781(81)90004-4.
6
Dopamine receptors in the Parkinsonian brain.
J Neural Transm. 1981;51(1-2):97-106. doi: 10.1007/BF01664007.
7
Methionine-enkephalin deficiency in brains of patients with Parkinson's disease.
Lancet. 1981 Jun 20;1(8234):1367-8. doi: 10.1016/s0140-6736(81)92543-5.
8
Parkinsonism: onset, progression and mortality.
Neurology. 1967 May;17(5):427-42. doi: 10.1212/wnl.17.5.427.
9
5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.
Life Sci. 1967 Jul 1;6(13):1449-54. doi: 10.1016/0024-3205(67)90193-2.
10
Relationship of monoamine metabolites in human cerebrospinal fluid to age.
Nature. 1968 Sep 21;219(5160):1256-7. doi: 10.1038/2191256a0.
Zotero 插件